1365378-58-0

Upstream product

• 1141741-64-1 (S)-tert-butyl 4-((R,E)-6-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)hex-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 1141741-65-2 C₂₃H₄₅NO₄Si 
• 1141741-66-3 (S)-tert-butyl 4-((R,E)-6-hydroxy-2-methylhex-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 1141741-67-4 (S)-tert-butyl 4-((S)-3-((2S,3S)-3-(hydroxymethyl)oxiran-2-yl)-2-methylpropyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 1141741-68-5 C₁₇H₃₀INO₄ 
• 1141741-69-6 (S)-tert-butyl 4-((2S,4S)-4-hydroxy-2-methylhex-5-enyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 100-39-0 benzyl bromide 
• 1141741-61-8 (S)-tert-butyl 4-((R,E)-2-((R)-4-benzyl-2-oxooxazolidin-3-carbonyl)-6-(tert-butyldimethylsilyloxy)hex-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate 

Downstream Products

• 1141741-70-9 (S)-tert-butyl 4-((2S,4S)-4-benzyloxy-6-hydroxy-2-methylhexyl)-2,2-dimethyloxazolidine-3-carboxylate 

Relevant academic research and scientific papers

Stereoselective synthesis of fully protected (2S,4S,6S)-2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD)

The stereocontrolled synthesis of fully protected (2S,4S,6S)-2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid was accomplished using a glutamate derivative as starting material. The key steps of this stereochemical synthetic pathway involved an Evans asymmetric alkylation, a Sharpless asymmetric epoxidation, and a Grignard reaction.